Barclays raises Kymera Therapeutics target price to $170 from $139
KYMR•Barclays raised its target price for Kymera Therapeutics to $170 from $139.
Related News
Bright Horizons Family Solutions: Barclays cuts target price to $80 from $95
BFAM•
Chevron Corporation: Evercore ISI raises target price to $250 from $225
CVX•
Nasdaq trade halt continues; reason not available at 03:58 am
OST•
Nasdaq trade halt continues; reason not available at 03:58 a.m.
UCFI•
UAE energy minister says Iran war’s course cannot be predicted, but UAE will be more prepared
USO•